Increased xCT expression correlates with tumor invasion and outcome in patients with glioblastomas

Neurosurgery

Volumn 72, Issue 1, 2013, Pages 33-41

  Takeuchi, Satoru ^a   Wada, Kojiro ^a   Toyooka, Terushige ^a   Shinomiya, Nariyoshi ^a   Shimazaki, Hideyuki ^a   Nakanishi, Kuniaki ^a   Nagatani, Kimihiro ^a   Otani, Naoki ^a   Osada, Hideo ^a   Uozumi, Yoichi ^a   Matsuo, Hirotaka ^a   Nawashiro, Hiroshi ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Glioblastoma; Glutamate; Magnetic resonance imaging; Prognostic factor; XCT

Indexed keywords

ANTIPORTER; ISOCITRATE DEHYDROGENASE 1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; XCT PROTEIN;

ADULT; AGED; ARTICLE; CANCER INVASION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GLIOBLASTOMA; HUMAN; KARNOFSKY PERFORMANCE STATUS; MALE; MINI MENTAL STATE EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AMINO ACID TRANSPORT SYSTEM Y+; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GLIOBLASTOMA; GLUTAMATE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; ISOCITRATE DEHYDROGENASE; KAPLAN-MEIER ESTIMATE; KARNOFSKY PERFORMANCE STATUS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEUROPSYCHOLOGICAL TESTS; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84871962040     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/NEU.0b013e318276b2de     Document Type: Article

References (40)

1. DeAngelis LM. Brain tumors. N Engl J Med. 2001;344(2):114-123.
2. Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007;21(21):2683-2710.
3. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359(5):492-507.
4. Curran WJ Jr, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993;85(9):704-710.
5. Mirimanoff RO, Gorlia T,Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol. 2006;24(16):2563-2569.
6. Diehn M, Nardini C, Wang DS, et al. Identification of noninvasive imaging surrogates for brain tumor geneYexpression modules. Proc Natl Acad Sci U S A. 2008;105(13):5213-5218.
7. Lacroix M, AbiYSaid D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95(2):190-198.
8. Cao VT, Jung TY, Jung S, et al. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas. Neurosurgery. 2009;65(5):866-875.
9. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997-1003.
10. Yan W, Zhang W, You G, et al. Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China. PLoS One. 2012;7(1):e30339.
11. Kaba SE, Kyritsis AP. Recognition and management of gliomas. Drugs. 1997;53 (2):235-244.
12. Ye ZC, Sontheimer H. Glioma cells release excitotoxic concentrations of glutamate. Cancer Res. 1999;59(17):4383-4391.
13. Behrens PF, Langemann H, Strohschein R, Draeger J, Hennig J. Extracellular glutamate and other metabolites in and around RG2 rat glioma: an intracerebral microdialysis study. J Neurooncol. 2000;47(1):11-22.
14. Takano T, Lin JH, Arcuino G, Gao Q, Yang J, Nedergaard M. Glutamate release promotes growth of malignant gliomas. Nat Med. 2001;7(9):1010-1015.
15. Savaskan NE, Heckel A, Hahnen E, et al. Small interfering RNAYmediated xCT silencing in gliomas inhibits neurodegeneration and alleviates brain edema. Nat Med. 2008;14(6):629-632.
16. Marcus HJ, Carpenter KL, Price SJ, Hutchinson PJ. In vivo assessment of highgrade glioma biochemistry using microdialysis: a study of energy-related molecules, growth factors and cytokines. J Neurooncol. 2010;97(1):11-23.
17. Lyons SA, ChungWJ,Weaver AK,Ogunrinu T, Sontheimer H. Autocrine glutamate signaling promotes glioma cell invasion. Cancer Res. 2007;67(19):9463-9471.
18. de Groot JF, Liu TJ, Fuller G, Yung WK. The excitatory amino acid transporterY2 induces apoptosis and decreases glioma growth in vitro and in vivo. Cancer Res. 2005;65(5):1934-1940.
19. Savaskan NE, Eyüpoglu IY. xCTmodulation in gliomas: relevance to energy metabolism and tumor microenvironment normalization. Ann Anat. 2010;192(5):309-313.
20. Chung WJ, Lyons SA, Nelson GM, et al. Inhibition of cystine uptake disrupts the growth of primary brain tumors. J Neurosci. 2005;25(31):7101-7110.
21. Lo M, Wang YZ, Gout PW. The x(c)Y cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. J Cell Physiol. 2008;215(3):593-602.
22. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROSYmediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov. 2009;8(7):579-591.
23. Chen RS, Song YM, Zhou ZY, et al. Disruption of xCT inhibits cancer cell metastasis via the caveolinY1/betaYcatenin pathway. Oncogene. 2009;28(4):599-609.
24. Sato H, Shiiya A, Kimata M, et al. Redox imbalance in cystine/glutamate transporterYdeficient mice. J Biol Chem. 2005;280(45):37423-37429.
25. Huang Y,Dai Z, Barbacioru C, SadéeW. CystineYglutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Res. 2005;65(16):7446-7454.
26. MacdonaldDR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277-1280.
27. Kleihues P, Burger PC, Aldape KD, et al. Glioblastoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. WHO Classification of Tumours of the Central Nervous System. Lyon, France: IARC; 2007:33-49.
28. Mikeska T, Bock C, ElYMaarri O, et al. Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J Mol Diagn. 2007;9(3):368-381.
29. Colella S, Shen L, Baggerly KA, Issa JP, Krahe R. Sensitive and quantitative universal pyrosequencing methylation analysis of CpG sites. Biotechniques. 2003;35(1):146-150.
30. Rietschel P, Wolchok JD, Krown S, et al. Phase II study of extendedYdose temozolomide in patients with melanoma. J Clin Oncol. 2008;26(14):2299-2304.
31. Bridges RJ, Natale NR, Patel SA. System xc cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS.Br J Pharmacol. 2012;165(1):20-34.
32. Bridges R, Lutgen V, Lobner D, Baker DA. Thinking outside the cleft to understand synaptic activity: contribution of the cystineYglutamate antiporter (System xcY) to normal and pathological glutamatergic signaling. Pharmacol Rev. 2012;64(3):780-802.
33. Conrad M, Sato H. The oxidative stressYinducible cystine/glutamate antiporter, system x (c) (Y) : cystine supplier and beyond. Amino Acids. 2012;42(1):231-246.
34. Lewerenz J, Maher P, Methner A. Regulation of xCT expression and system x (c) (Y) function in neuronal cells. Amino Acids. 2012;42(1):171-179.
35. Burdo J, Dargusch R, Schubert D. Distribution of the cystine/glutamate antiporter system xcY in the brain, kidney, and duodenum. J Histochem Cytochem. 2006;54 (5):549-557.
36. Cho Y, Bannai S. Uptake of glutamate and cysteine in CY6 glioma cells and in cultured astrocytes. J Neurochem. 1990;55(6):2091-2097.
37. Robe PA, Martin DH, NguyenYKhac MT, et al. Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults. BMC Cancer. 2009;9:372.
38. Shi ZZ, OseiYFrimpong J, Kala G, et al. Glutathione synthesis is essential for mouse development but not for cell growth in culture. Proc Natl Acad Sci U S A. 2000;97(10):5101-5106.
39. Combs SE, Rieken S, Wick W, et al. Prognostic significance of IDHY1 and MGMT in patients with glioblastoma: one step forward, and one step back? Radiat Oncol. 2011;6(1):115.
40. Costa BM, Caeiro C, Guimarães I, et al. Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomideYbased chemoradiation: a Portuguese multicentre study. Oncol Rep. 2010;23(6):1655-1662.